Latest News


PAT KENNY SHOW talk available as podcast

Dublin 27 March 2017 PAT KENNY SHOW Ireland feature Oncofocus “a Revolutionary test can tailor the best therapy for cancer patients” GUESTS: Dr David Fennelly Oncologist at St Vincent’s Hospital and Blackrock clinic DUBLIN Prof Gareth H Williams Oncologica Ltd Medical Director

Read More

revolutionary new test

Oncofocus a revolutionary test that can tailor the best therapy for cancer patients

A revolutionary new test, which takes the “guesswork” out of deciding what treatment will be most effective for a cancer patient, has been launched in Ireland. Dr David Fennelly, oncologist at St Vincent’s Hospital in Dublin, said the Oncofocus test has great potential to improve the survival of cancer patients. This will include not just […]

Read More

Oncologica live on The Pat Kenny Show – IRELAND

Oncologica will be guest on The Pat Kenny Show – IRELAND Monday 27th March 2017, 9:30- 10:30am

Read More

Binimetinib Improves PFS in NRAS-mutant Melanoma

Binimetinib significantly prolonged progression-free survival compared with dacarbazine and was associated with a manageable safety profile among patients with advanced, NRAS-mutant melanoma, according to a study published in The Lancet Oncology.1 For the ongoing, international, open-label, phase 3 NEMO trial ( Identifier: NCT01763164), researchers evaluated the efficacy and safety of binimetinib, a MEK inhibitor, compared […]

Read More

New Insights Into Rucaparib Activity in Ovarian Cancer

The PARP inhibitor rucaparib slowed progression of relapsed BRCA-mutant ovarian cancer regardless of whether the mutations were somatic or germline, a new analysis of a phase II trial showed. Patients with germline or somatic BRCA mutations had a median progression-free survival (PFS) of about 13 months when treated with rucaparib. Additionally, patients with BRCA1 or […]

Read More


NICE says yes to Novartis’ Afinitor in kidney cancer

Novartis’ Afinitor (everolimus) has received backing from UK cost-effectiveness body NICE for routine use in patients with advanced kidney cancer. The drug is now available as a second-line treatment in cases of advanced renal cell carcinoma that has progressed during or following treatment with vascular endothelial growth factor (VEGF)-targeted therapy. The decision follows a positive […]

Read More

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with T790M-positive, advanced non-small cell lung cancer (NSCLC) who progress after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment, according to a study published in the Journal of Clinical Oncology.1 The phase 2 extension component of the multicenter, open-label, phase […]

Read More

Immunotherapy, Molecular Testing Propel Dramatic Changes in Lung Cancer Care

2017 is poised to be another pivotal year in non–small cell lung cancer (NSCLC), given the exciting advances in field at the end of last year. In October 2016, the FDA approved pembrolizumab (Keytruda) for the frontline treatment of patients with metastatic NSCLC whose tumors have more than 50% PD-L1 expression. The agent was previously […]

Read More

Mutation-Targeted Therapy Slows Lung Cancer (NSCLC)

Patients with previously treated advanced non-small cell lung cancer (NSCLC) lived more than twice as long without disease progression when treated with a drug that targets a key resistance mutation versus standard chemotherapy, investigators reported. Treatment with the oral tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) led to a median progression-free survival (PFS) of 10.1 months […]

Read More

Lung Cancer Driver Discovery May Lead to Novel Therapy for Some Mesothelioma Patients

Lung adenocarcinoma, the most aggressive subtype of non-small cell lung cancer (NSCLC), comprises nearly 40 percent of lung cancer diagnoses. The KRAS gene is the most significant driver of this cancer, and is also found in some pleural mesothelioma cases. Researchers have been stymied by this tough gene that nearly always fights off treatments building […]

Read More

Olaratumab May Improve Disease Control in Certain Patients With GIST

Olaratumab had an acceptable safety profile and may improve disease control in patients with PDGFRα mutation-positive gastrointestinal stromal tumor (GIST), according to a study published in Annals of Oncology.1 This open-label, phase 2 study ( Identifier: NCT01316263) enrolled 30 previously treated patients with unresectable and/or metastatic GIST regardless of PDGFRα mutation status. All PDGFRα mutations […]

Read More

Imatinib and GISTs: Genomic Subtypes and Survival Outcomes

Some unresectable gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations respond to imatinib therapy and may extend a patient’s overall survival by as much as a decade, according to an article published in JAMA Oncology.1 Chemotherapy is notoriously ineffective for patients with a metastatic or unresectable GIST; it was shown, however, that GISTs with […]

Read More